Sign In
Home
About
Main Menu
Overview
Leadership Board
Program Partners
Affiliates
News Center
Contact
Advocacy
Main Menu
Featured
Insights & POV
Roundtables
Reports
Knowledge Center
Featured
Events
Industry News
Transform Tech TV
Sign In
Edit Fact
Text
Just over two years http://fuq.in.net/ www fuq.com That could bode well for a second Phase III trial of Yervoy, expected to be completed by 2015, which has enrolled patients who are asymptomatic or have only mild symptoms of prostate cancer, and whose cancer has not spread to the lungs or liver. Although previously treated with anti-testosterone drugs, they have not taken chemotherapy.
Publication
Url
Actions
Delete
List Facts